Judd Jessup has over 35 years of experience in the healthcare and managed care industries. Most recently he was Chief Executive Officer at CombiMatrix, a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders, where he served from August 2010 to March 2013. Formerly he held the position of CEO at US LABS, a national laboratory which provides cancer diagnostic and genetic testing services, from 2002 to 2005. He has extensive background in the managed care industry having served as President of the Health Plans Division for FHP International from 1994 to 1996 as well as the President of TakeCare, Inc., a publicly traded HMO operating in California, Colorado, Illinois and Ohio until it was sold to FHP. He is a successful entrepreneur with the ability to execute strategic plans to achieve the optimum level of performance for stakeholders. He has repeatedly built effective management teams utilizing his effective leadership and management style. Mr. Jessup currently serves on the Board of Directors of Corvel Corporation and NovaMed, Inc, both publicly traded companies.
Mr. McDonough brings over 16 years of experience in diagnostic healthcare and life sciences to CombiMatrix. Led by his passion for patient care, he has spent his career growing early stage and emerging cancer diagnostics, molecular diagnostics and commercial laboratory organizations.
In August 2012, Mr. McDonough joined CombiMatrix as Chief Commercial Officer. His efforts to optimize the commercial aspects of CombiMatrix and his focus on prenatal testing have made an immediate impact on the Company’s long-term strategy and financial success. Mr. McDonough came to CombiMatrix from Pathwork Diagnostics where he was Vice President of Sales and Service. His business acumen was instrumental in driving all phases of their commercial efforts, including sales, reimbursement strategies and market creation of novel diagnostics that fulfilled a critical, yet unmet need for patients with metastatic disease.
Preceding Pathwork Diagnostics, Mr. McDonough held positions of increasing responsibility at US LABS, ultimately assuming the role of Vice President of Sales. He also served in an executive capacity at Dianon and Laboratory Corporation of America (post acquisition). His contributions as a field sales resource and sales leader from 2002-2004 were instrumental in the growth of US LABS from $17M to $75M, resulting in the successful acquisition by Laboratory Corporation of America in early 2005. Mr. McDonough was with EMC Corporation and Ventana Medical Systems previous to US LABS.
Prior to entering the healthcare industry, Mr. McDonough was a ranking officer in the United States Navy for six years where he served as Navigator of the USS FLETCHER (DD 992).
Mr. McDonough received a Bachelor’s Degree in Finance from Miami University-Ohio.
Robert E. Hoffman
Robert E. Hoffman has served on our Board since July 2013. He is the Chief Financial Officer and Senior Vice President, Finance of Heron Therapeutics, Inc., a publicly traded commercial-stage biotechnology company since April 2017. He was the Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a publicly traded pharmaceuticals company, where he served from September 2016 to April 2017. Mr. Hoffman was the Chief Financial Officer of AnaptysBio, Inc., a biopharmaceutical company, where he has served from July 2015 to September 2016. Mr. Hoffman was the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, until July 2015 where he had served in various finance and accounting roles since 1997, except that from March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a privately held drug development company. Mr. Hoffman is a member of the business and financial advisory board of Innovus Pharmaceuticals, a publicly traded pharmaceuticals company. Mr. Hoffman also serves as a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman is also a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a bachelor’s degree in business administration from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California. Mr. Hoffman is also a member of the board of directors of MabVax Therapeutics Holdings, Inc. and Kura Oncology, Inc.
Jeremy M. Jones was appointed to our Board on November 20, 2012 and is also a member of our Audit Committee. Mr. Jones, 70, is the Chairman of On Assignment, Inc., a publicly traded professional staffing firm, where he has served as a director since May 1995. Mr. Jones has been an investor and business development consultant since February 1998. From 1987 to 1995, Mr. Jones was Chief Executive Officer and Chairman of the Board of Homedco Group, Inc., a home healthcare services company, which became publicly traded in 1991. Homedco merged into Apria Healthcare Group, Inc. in 1995 and from 1995 through January 1998, Mr. Jones was Chief Executive Officer and Chairman of the Board of Apria Healthcare Group, Inc., which also provided home healthcare services. Mr. Jones served as Chairman of the Board of Byram Healthcare Centers, a provider of retail medical supplies and wholesale medical and hospital equipment, from February 1999 until its sale in March of 2008. Mr. Jones was a director for Access Point Medical from May 2004 to December 2005. Mr. Jones was a director of US Labs, an esoteric oncology and hematopathology laboratory from November 2003 through February 2005. From July 2003 to January 2011, Mr. Jones served as a director for Lifecare Solutions, Inc., a provider of integrated home healthcare products and services. Mr. Jones holds a bachelor’s degree in business administration from the University of Iowa.
Lâle White, currently CEO of XIFIN, Inc., is a nationally recognized expert in the field of healthcare financial management and regulatory compliance, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program. She is a member of the Board of Directors of bioTheranostics, part of the worldwide bioMerieux group, and is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services. Ms. White was previously vice president - finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White has a BA in finance and an MBA from Florida International University
Dirk van den Boom, Ph.D., is the founder and Managing Partner of mindwerks bio, LLC, a San Diego-based research and development stage life sciences company, and also serves as a Senior Advisor to Berg Capital Markets, a Healthcare capital markets and analytics firm. Previously, Dr. van den Boom served as President, Chief Executive Officer and Director of Sequenom, Inc., a publicly-traded healthcare diagnostics company that was acquired by LabCorp in September 2016. Dr. van den Boom joined Sequenom in 1998 and held positions of increasing responsibility during his 18-year tenure at Sequenom, including as President and Chief Executive Officer from October 2015 to September 2016, Director from April 2015 to September 2016, Chief Scientific and Strategy Officer from June 2014 to October 2015, Executive Vice President of Research and Development and Chief Technology Officer from December 2012 to June 2014, Senior Vice President of Research and Development from August 2010 to December 2012 and Vice President of Research and Development from October 2009 to August 2010. Prior to August 2010, he held various management roles within the research and development departments of Sequenom. Dr. van den Boom also has served as a Member of the March of Dimes Board of Directors, San Diego Chapter since December 2015. Dr. van den Boom has co-authored over 95 peer-reviewed publications and is a named inventor on over 80 patents and patent applications. He received his Ph.D in Biochemistry/Molecular Biology from the University of Hamburg, Germany.